A Novel Cell Line for Screening of Immunosuppressor Specific to T Lymphocytes.
- Author:
Sang Kyou LEE
;
Jung Hee LIM
;
Kyung Min CHO
;
Seung Hyo LEE
;
Yong Sup SONG
;
Hyoung Sik CHUN
;
Hyeog Jin SON
- Publication Type:Original Article
- Keywords:
NFAT;
SEAP assay;
T lymphocyte;
Immunosuppressor
- MeSH:
Alkaline Phosphatase;
Bacteria;
Binding Sites;
Cell Line*;
Cyclosporine;
Fungi;
Interleukin-2;
Ionomycin;
Kidney;
Mass Screening*;
Muromonab-CD3;
Receptors, Antigen, T-Cell;
T-Lymphocytes*;
Tacrolimus;
Transplants
- From:Korean Journal of Immunology
1997;19(3):375-382
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The systematic study of products from bacteria and fungi has led to the development of two immunosuppressive drugs, cyclosporin A and FK 506 (tacrolimus) which are useful to suppress adaptive immune responses to the grafted tissue. However, they affect all immune responses indiscriminately and are both toxic to kidneys and other organs. To facilitate the development of immunosuppressor to block the T cell receptor (TcR)-mediated signaling cascade specifically, a novel Jurkat T cell transfectants, JK NFAT-SEAP were generated in which the expression of the secreted alkaline phosphatase (SEAP) is driven by the multiple NFAT binding sites plus minimal IL-2 promoter. Upon stimulation with ionomycin or anti-TcR mAb OKT3 in the presence of PMA, these transfectants secreted high level of SEAP into the medium, which was conveniently analyzed by SEAP analysis. The secretion of SEAP was effectively inhibited by cyclosporin A or FK 506 at the concentration of [10 ' ug/ml], [10 ug/ml] respectively. JK NFAT-SEAP transfectants will provide two major advantages for the development of a novel immunosuppressor. First, analysis of SEAP secreted into the culture medium by SEAP analysis enables us to test a large number of samples within a short period of time. Second, Usage of IL-2 promoter for the expression of SEAP makes us identify bioproducts to target specifically on TcR-mediated signaling pathway.
